Numinus Wellness (NUMI) AI Stock Analysis

• Market Cap: C$13.86M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 200
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 320,551,600
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score for Numinus Wellness is primarily impacted by its poor financial performance, characterized by declining revenues and high operating losses. The technical analysis indicates a neutral position with no clear trend, while the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall score, highlighting significant challenges for the company.

Positive Factors

Innovative Business Model

Numinus's focus on psychedelic-assisted therapies positions it as a leader in an emerging field, potentially capturing a growing market in mental health solutions.

Diverse Revenue Streams

Multiple revenue streams from clinical services, research, and training provide resilience against market fluctuations and enhance long-term financial stability.

Strategic Partnerships

Collaborations with academic and mental health institutions enhance research capabilities and market reach, bolstering long-term growth potential and innovation.

Negative Factors

Revenue Decline

A steep decline in revenue growth indicates challenges in market penetration and product adoption, threatening long-term sustainability and competitive position.

High Operating Losses

Substantial operating losses undermine profitability, limiting the company's ability to reinvest in growth initiatives and posing a risk to financial health.

High Leverage

Significant leverage increases financial risk, potentially constraining cash flow and reducing flexibility in strategic decision-making, impacting long-term viability.

Numinus Wellness Business Overview & Revenue Model

Company Description

Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

Numinus Wellness generates revenue through multiple streams, primarily from its clinical services, research initiatives, and partnerships. The company earns income by providing therapeutic treatment programs that utilize psychedelic substances, alongside conducting clinical trials which may be funded by partnerships with pharmaceutical companies and research institutions. Additionally, Numinus offers training programs for healthcare professionals in psychedelic therapy, creating another revenue stream. Significant partnerships with academic institutions and other entities in the mental health and wellness space also contribute to its earnings, enabling the company to leverage external funding and collaborative opportunities.

Numinus Wellness Financial Statement Overview

Summary

Numinus Wellness is facing significant financial challenges, with declining revenues, high operating losses, and substantial leverage. The company needs to address its cash flow issues and improve profitability to enhance financial stability. The current financial position suggests a need for strategic adjustments to achieve sustainable growth.

Income Statement

Numinus Wellness has experienced significant revenue decline with a negative growth rate of -80.55% in the latest period. The company is facing substantial losses, as indicated by a negative net profit margin of -471.23% and negative EBIT and EBITDA margins. Despite a positive gross profit margin of 27.97%, the overall profitability is severely impacted by high operating losses.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 2.80, indicating significant leverage and potential financial risk. Return on equity is negative at -27.08%, reflecting poor profitability relative to shareholder's equity. The equity ratio is low, suggesting limited equity financing relative to total assets.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash outflows from operations. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, albeit both are negative. The company has shown some improvement in free cash flow growth, but overall cash flow health remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-1.93M	4.17M	3.75M	6.49M	1.51M	881.18K
Gross Profit	-796.79K	1.17M	8.37M	1.78M	-81.54K	88.05K
EBITDA	-15.28M	-13.94M	-26.66M	-42.85M	-17.94M	-9.02M
Net Income	-19.65M	-19.64M	-30.26M	-44.88M	-18.77M	-9.60M
Balance Sheet
Total Assets	4.58M	10.77M	24.33M	52.63M	64.14M	5.12M
Cash, Cash Equivalents and Short-Term Investments	705.63K	1.96M	8.58M	33.04M	59.29M	1.63M
Total Debt	2.54M	2.03M	7.20M	7.85M	1.60M	421.63K
Total Liabilities	5.39M	10.05M	10.28M	11.42M	3.31M	2.32M
Stockholders Equity	-816.10K	725.43K	14.05M	41.21M	60.83M	2.80M
Cash Flow
Free Cash Flow	-13.63M	-17.50M	-23.14M	-27.48M	-16.22M	-5.39M
Operating Cash Flow	-13.45M	-17.48M	-22.76M	-26.23M	-15.58M	-5.36M
Investing Cash Flow	1.18M	860.08K	-369.57K	123.19K	-739.25K	-128.69K
Financing Cash Flow	-1.21M	4.54M	-1.46M	7.34K	73.98M	7.02M

Numinus Wellness Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NUMI, the sentiment is Negative. The current price of 0.04 is equal to the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.58 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NUMI.

Numinus Wellness Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	61 Neutral	C$27.94M	168.42	0.69%	―	11.89%	5.56%
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
NUMI	41 Neutral	C$13.86M	―		―	―	―
JNHMF	―	$298.43K	―		―	―	―
PHA	41 Neutral	C$1.67M	―	-1473.72%	―	-22.61%	7.72%
CALM	―	C$1.37M	―		―	―	―

Numinus Wellness Corporate Events

Numinus Wellness Reports Strong Q1 2025 Financial Results

Numinus Wellness Inc. reported a significant improvement in its financial performance for the first quarter of fiscal 2025, with a 68.3% increase in total revenue and a 121.1% rise in gross profit compared to the same period last year. This financial growth reflects the company’s strategic focus on expanding its innovative mental health care services, positioning it as a leader in the integration of psychedelic-assisted therapies, which could have positive implications for stakeholders and the broader mental health industry.

Numinus Wellness Reports Q4 Fiscal 2024 Results and Strategic Developments

Numinus Wellness Inc. reported a 16.4% increase in revenue for Q4 Fiscal 2024, achieving a gross profit of $0.3 million and a cash position of $2.0 million. The company has transitioned to a leaner operation, focusing on its Cedar Clinical Research and practitioner training businesses, which are experiencing robust growth. Significant developments include the sale of its U.S. Clinic Network to Stella, leadership changes with Michael Tan as CEO, and the approval of its Psychedelic-Assisted Therapy Training Program in Colorado. These strategic moves are expected to enhance the company’s position in the mental health industry and provide new growth opportunities.